Table 1 Correlations between absolute lymphocyte counts and clinicopathological parameters in 88 patients with eribulin chemotherapy for locally advanced or metastatic breast cancer
Parameters | All breast cancer (n = 88) | Progression due to new metastasis (n = 17) | Progression due to preexisting lesions (n = 71) | ||||||
|---|---|---|---|---|---|---|---|---|---|
High (n = 37) | Low (n = 51) | p value | High (n = 5) | Low (n = 12) | p value | High (n = 32) | Low (n = 39) | p value | |
Age at chemotherapy | |||||||||
≤ 63 | 24 (64.9%) | 28 (54.9%) | 3 (60.0%) | 6 (50.0%) | 21 (65.6%) | 22 (56.4) | |||
> 63 | 13 (35.1%) | 23 (45.1%) | 0.348 | 2 (40.0%) | 6 (50.0%) | 0.563 | 11 (34.4%) | 17 (43.6%) | 0.293 |
Degree of progress | |||||||||
Locally advanced | 11 (29.7%) | 13 (25.5%) | 1 (20.0%) | 5 (41.7%) | 10 (31.3%) | 8 (20.5%) | |||
Visceral metastases | 26 (70.3%) | 38 (74.5%) | 0.659 | 4 (80.0%) | 7 (58.3%) | 0.395 | 22 (68.7%) | 31 (79.5%) | 0.301 |
HR (ER and/or PgR) status | |||||||||
Negative | 12 (32.4%) | 21 (41.2%) | 1 (20.0%) | 6 (50.0%) | 11 (34.4%) | 15 (38.5%) | |||
Positive | 25 (67.6%) | 30 (58.8%) | 0.403 | 4 (80.0%) | 6 (50.0%) | 0.278 | 21 (65.6%) | 24 (61.5%) | 0.722 |
HER2 status | |||||||||
Negative | 33 (89.2%) | 47 (92.2%) | 5 (100.0%) | 12 (100.0%) | 28 (87.5%) | 35 (89.7%) | |||
Positive | 4 (10.8%) | 4 (7.8%) | 0.633 | 0 (0.0%) | 0 (0.0%) | - | 4 (12.5%) | 4 (10.3%) | 0.527 |
Ki67 | |||||||||
Low | 21 (56.8%) | 30 (58.8%) | 2 (40.0%) | 4 (33.3%) | 19 (59.4%) | 26 (66.7%) | |||
High | 16 (43.2%) | 21 (41.2%) | 0.846 | 3 (60.0%) | 8 (66.7%) | 0.605 | 13 (40.6%) | 13 (33.3%) | 0.526 |
Nuclear grade | |||||||||
1, 2 | 24 (64.9%) | 38 (74.5%) | 3 (60.0%) | 8 (66.7%) | 21 (65.6%) | 30 (76.9%) | |||
3 | 13 (35.1%) | 13 (25.5%) | 0.328 | 2 (40.0%) | 4 (33.3%) | 0.605 | 11 (34.4%) | 9 (23.1%) | 0.292 |
Objective response rate | |||||||||
ORR | 23 (62.2%) | 18 (35.3%) | 3 (60.0%) | 2 (16.7%) | 20 (62.5%) | 16 (41.0%) | |||
Non-ORR | 14 (37.8%) | 33 (64.7%) | 0.013 | 2 (40.0%) | 10 (83.3%) | 0.117 | 12 (37.5%) | 23 (59.0%) | 0.072 |